Sponsored by Collegium Pharmaceutical, Inc.
This activity is not certified for credit.
Friday, September 8
This program will discuss key issues around opioid abuse, misuse, and diversion. An overview of opioid formulations with abuse-deterrent properties will be provided before featuring a description of the DETERx® microsphere delivery system and summarizing the Xtampza® ER (oxycodone) clinical profile. Xtampza® ER is Collegium's first product utilizing the DETERx® technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
DETERx is a registered trademark of Collegium Pharmaceutical, Inc.
Gerard DeGregoris, III, MD
Pre-registration not required. Please arrive at least 15 minutes prior to start time.
Sheri Selvey, PharmD
Posted on August 16, 2017